Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1- benzoxazepines
Metadatos
Mostrar el registro completo del ítemAutor
Cruz López, Olga María; Ner, Matilde; Jiménez Martínez, Yaiza; Marchal Corrales, Juan Antonio; Boulaiz Tassi, Houria; Campos Rosa, Joaquín María; Conejo García, AnaEditorial
Taylor & Francis
Materia
Antitumour Pyroptosis HER2 receptor Molecular modelling Benzoxazepines
Fecha
2021-07-12Referencia bibliográfica
Olga Cruz-López... [et al.] (2021) Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines, Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1, 1553-1563, DOI: [10.1080/14756366.2021.1948841]
Patrocinador
Junta de Andalucia P18-RT-1679; Oficina de Transferencia de Resultados de Investigacion of the University of Granada PR/17/006; Instituto de Salud Carlos III European Commission RTI2018-101309-B-C22; Instituto de Salud Carlos III FMM-AP16683-2017; Junta de Andalucia PI-0089-2017Resumen
A series of 11 new substituted 1,5-dihydro-4,1-benzoxazepine derivatives was synthesised to study the
influence of the methyl group in the 1-(benzenesulphonyl) moiety, the replacement of the purine by the
benzotriazole bioisosteric analogue, and the introduction of a bulky substituent at position 6 of the purine,
on the biological effects. Their inhibition against isolated HER2 was studied and the structure–activity
relationships have been confirmed by molecular modelling studies. The most potent compound against
isolated HER2 is 9a with an IC50 of 7.31 mM. We have investigated the effects of the target compounds on
cell proliferation. The most active compound (7c) against all the tumour cell lines studied (IC50
0.42–0.86 mM) does not produce any modification in the expression of pro-caspase 3, but increases the
caspase 1 expression, and promotes pyroptosis.